Drug delivery to macrophages: a review of nano-therapeutics targeted approach for inflammatory disorders and cancer

References

• Ahmed AU. An overview of inflammation: mechanism and consequences. Front Biol. 2011;6(4):274.
   Google Scholar
• Kelly C, Jefferies C, Cryan S-A. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv. 2011;2011:1–11.
   PubMedGoogle Scholar
• Jain NK, Mishra V, Mehra NK. Targeted drug delivery to macrophages. Expert Opin Drug Deliv. 2013;10(3):353–367.
   PubMed Web of Science ®Google Scholar
• Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6. doi:10.12703/P6-13
   PubMedGoogle Scholar
• *Novak ML, Koh TJ. Macrophage phenotypes during tissue repair. J Leukoc Biol. 2013;93(6):875–881.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15(5):271–282.
   PubMed Web of Science ®Google Scholar
• Headland SE, Norling LV. The resolution of inflammation: principles and challenges. In: Seminars in immunology. Elsevier; 2015.
   Google Scholar
• Moore E, Suresh V, Ying G, et al. M0 and M2 macrophages enhance vascularization of tissue engineering scaffolds. Regen Eng Transl Med. 2018;4(2):51–61.
   Web of Science ®Google Scholar
• Mills EL, Kelly B, Logan A, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell. 2016;167(2):457–470. e13.
   PubMed Web of Science ®Google Scholar
• Zeeshan M, Ali H, Khan S, et al. Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease. Int J Pharm. 2019;558:201–214.
   PubMed Web of Science ®Google Scholar
• Jahagirdar P. Mannose receptor and targeting strategies. In: Targeted intracellular drug delivery by receptor mediated endocytosis, edited by Padma V. Devarajan, Prajakta Dandekar, and Anisha A. D’Souza. AAPS Advances in the Pharmaceutical Sciences Series. Cham: Springer International Publishing,  2019. p. 433-456.
   Google Scholar
• Suzuki Y, Shirai M, Asada K, et al. Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis. Sci Rep. 2018;8(1):13129.
   PubMedGoogle Scholar
• Lokhande AS, Jahagirdar P, Dandekar P, et al. Scavenger receptor and targeting strategies. In: Targeted intracellular drug delivery by receptor mediated endocytosis, edited by Padma V. Devarajan, Prajakta Dandekar, and Anisha A. D’Souza. AAPS Advances in the Pharmaceutical Sciences Series. Cham: Springer International Publishing, 2019. p. 297-321.
   Google Scholar
• Ahmed M, Baumgartner R, Aldi S, et al. Human serum albumin-based probes for molecular targeting of macrophage scavenger receptors. Int J Nanomedicine. 2019;14:3723.
   PubMed Web of Science ®Google Scholar
• He S, Liang Y, Shao F, et al. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3–mediated pathway. Proc Nat Acad Sci. 2011;108(50):20054–20059.
   PubMed Web of Science ®Google Scholar
• Anwar MA, Shah M, Kim J, et al. Recent clinical trends in Toll‐like receptor targeting therapeutics. Med Res Rev. 2019;39(3):1053–1090.
   PubMed Web of Science ®Google Scholar
• Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin Chim Acta. 2012;413(1–2):3–14.
   PubMed Web of Science ®Google Scholar
• Lea SR, Reynolds S, Kaur M, et al. The effects of repeated Toll-like receptors 2 and 4 stimulation in COPD alveolar macrophages. Int J Chron Obstruct Pulmon Dis. 2018;13:771.
   PubMed Web of Science ®Google Scholar
• Chaung H-C, Huang T-C, Yu J-H, et al. Immunomodulatory effects of β-glucans on porcine alveolar macrophages and bone marrow haematopoietic cell-derived dendritic cells. Vet Immunol Immunopathol. 2009;131(3–4):147–157.
   PubMed Web of Science ®Google Scholar
• Soto ER, O’Connell O, Dikengil F, et al. Targeted delivery of glucan particle encapsulated gallium nanoparticles inhibits HIV growth in human macrophages. J Drug Deliv. 2016;2016:1–8.
   PubMed Web of Science ®Google Scholar
• Sun JY, Shen J, Thibodeaux J, et al. In vivo optical imaging of folate receptor‐β in head and neck squamous cell carcinoma. Laryngoscope. 2014;124(8):E312–E319.
   PubMed Web of Science ®Google Scholar
• O’Shannessy DJ, Somers EB, Wang L-C, et al. Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers. J Ovarian Res. 2015;8(1):29.
   PubMedGoogle Scholar
• Genua M, Rutella S, Correale C, et al. The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis. J Transl Med. 2014;12(1):293.
   PubMed Web of Science ®Google Scholar
• Xiao B, Laroui H, Ayyadurai S, et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapy. Biomaterials. 2013;34(30):7471–7482.
   PubMed Web of Science ®Google Scholar
• *Zhang M, Xu C, Liu D, et al. Oral delivery of nanoparticles loaded with ginger active compound, 6-shogaol, attenuates ulcerative colitis and promotes wound healing in a murine model of ulcerative colitis. J Crohn’s Colitis. 12(2):217–229. 2018. .
   Google Scholar
• Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628–1640.
   PubMed Web of Science ®Google Scholar
• Poh S, Chelvam V, Ayala-López W, et al. Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases. Nanomedicine. 2018;14(3):1033–1043.
   PubMed Web of Science ®Google Scholar
• Lee Y, Sugihara K, Gillilland MG, et al. Hyaluronic acid–bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater. 2019;1–9.
   PubMed Web of Science ®Google Scholar
• Sarwar HS, Akhtar S, Sohail MF, et al. Redox biology of Leishmania and macrophage targeted nanoparticles for therapy. Nanomedicine. 2017;12(14):1713–1725.
   PubMed Web of Science ®Google Scholar
• Alexandru-Flaviu T, Cornel C. Macrophages targeted drug delivery as a key therapy in infectious disease. BMBN. 2014;2(1):17–20.
   Google Scholar
• Sarwar HS, Varikuti S, Sohail MF, et al. Oral delivery and enhanced efficacy of antimonal drug through macrophage-guided multifunctional nanocargoes against visceral Leishmaniasis. Eur J Pharm Biopharm. 2020.
   PubMed Web of Science ®Google Scholar
• Chaubey P, Mishra B. Mannose-conjugated chitosan nanoparticles loaded with rifampicin for the treatment of visceral leishmaniasis. Carbohydr Polym. 2014;101:1101–1108.
   PubMed Web of Science ®Google Scholar
• Afzal I, Sarwar HS, Sohail MF, et al. Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis. Nanomedicine. 2019;14(4):387–406.
   PubMed Web of Science ®Google Scholar
• Chaubey P, Mishra B, Mudavath SL, et al. Mannose-conjugated curcumin-chitosan nanoparticles: efficacy and toxicity assessments against Leishmania donovani. Int J Biol Macromol. 2018;111:109–120.
   PubMed Web of Science ®Google Scholar
• Biswaro LS, Garcia MP, da Silva JR, et al. Itraconazole encapsulated PLGA‐nanoparticles covered with mannose as potential candidates against leishmaniasis. J Biomed Mater Res Part B. 2019;107(3):680–687.
   PubMed Web of Science ®Google Scholar
• Singh PK, Jaiswal AK, Pawar VK, et al. Fabrication of 3-O-sn-phosphatidyl-L-serine anchored PLGA nanoparticle bearing amphotericin B for macrophage targeting. Pharm Res. 2018;35(3):60.
   PubMed Web of Science ®Google Scholar
• Guirado E, Schlesinger LS, Kaplan G. Macrophages in tuberculosis: friend or foe. In: Seminars in immunopathology. . 2013;35(5):563–83.
   Google Scholar
• Knight M, Braverman J, Asfaha K, et al. Lipid droplet formation in Mycobacterium tuberculosis infected macrophages requires IFN-γ/HIF-1α signaling and supports host defense. PLoS Pathog. 2018;14(1):e1006874.
   PubMed Web of Science ®Google Scholar
• Guirado E, Schlesinger L. Modeling the Mycobacterium tuberculosis granuloma–the critical battlefield in host immunity and disease. Front Immunol. 2013;4:98.
   PubMed Web of Science ®Google Scholar
• Pi J, Shen L, Yang E, et al. Macrophage‐targeted isoniazid–selenium nanoparticles promote antimicrobial immunity and synergize bactericidal destruction of tuberculosis bacilli. Angew Chem. 2020;59(8):3226–3234.
   Google Scholar
• Choi S-R, Britigan BE, Moran DM. et al. Gallium nanoparticles facilitate phagosome maturation and inhibit growth of virulent Mycobacterium tuberculosis in macrophages. PLoS One. 2017;12(5).
   Web of Science ®Google Scholar
• Maretti E, Costantino L, Rustichelli C, et al. Surface engineering of solid lipid nanoparticle assemblies by methyl α-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy. Int J Pharm. 2017;528(1–2):440–451.
   PubMedGoogle Scholar
• Pi J, Shen L, Yang E, et al. Macrophage‐targeted isoniazid‐selenium nanoparticles promote innate immunity, inducing synergistic antimicrobial and bactericidal destructions of tuberculosis bacilli. Angew Chem. 2019.
   Google Scholar
• Basha RY, TS SK, Doble M. Dual delivery of tuberculosis drugs via cyclodextrin conjugated curdlan nanoparticles to infected macrophages. Carbohydr Polym. 2019;218:53–62.
   PubMed Web of Science ®Google Scholar
• Mefford ME, Kunstman K, Wolinsky SM, et al. Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5. Virology. 2015;481:210–222.
   PubMed Web of Science ®Google Scholar
• Herskovitz J, Gendelman HE. HIV and the macrophage: from cell reservoirs to drug delivery to viral eradication. J Neuroimmune Pharmacol. 2019;14(1):52–67.
   PubMed Web of Science ®Google Scholar
• Rappaport J, Volsky DJ. Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment. J Neurovirol. 2015;21(3):235–241.
   PubMed Web of Science ®Google Scholar
• Mobarakeh VI, Modarressi MH, Rahimi P, et al. Optimization of chitosan nanoparticles as an anti-HIV siRNA delivery vehicle. Int J Biol Macromol. 2019;129:305–315.
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Fogagnolo M, Ferraro L, et al. Bile salt-coating modulates the macrophage uptake of nanocores constituted by a zidovudine prodrug and enhances its nose-to-brain delivery. Eur J Pharm Biopharm. 2019;144:91–100.
   PubMed Web of Science ®Google Scholar
• Urbaniak T, Machová D, Janoušková O, et al. Microparticles of lamivudine—poly-ε-caprolactone conjugate for drug delivery via internalization by macrophages. Molecules. 2019;24(4):723.
   Web of Science ®Google Scholar
• **Ao Z, Wang L, Mendoza EJ, et al. Incorporation of Ebola glycoprotein into HIV particles facilitates dendritic cell and macrophage targeting and enhances HIV-specific immune responses. PloS One. 2019; 14(5)
   Web of Science ®Google Scholar
• **Khan T, Mayuresh Patkar M, Momin M, et al. Macrophage targeted nanocarrier delivery systems in HIV therapeutics. Expert Opin Drug Deliv. 2020;(just–accepted).
   Google Scholar
• Nogueira E, Gomes AC, Preto A, et al. Folate-targeted nanoparticles for rheumatoid arthritis therapy. Nanomedicine. 2016;12(4):1113–1126.
   PubMed Web of Science ®Google Scholar
• Lacerte P, Brunet A, Egarnes B, et al. Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists. Arthritis Res Ther. 2016;18(1):10.
   PubMedGoogle Scholar
• Thomas TP, Goonewardena SN, Majoros IJ, et al. Folate‐targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheumatism. 2011;63(9):2671–2680.
   PubMed Web of Science ®Google Scholar
• Jain S, Tran T-H, Amiji M. Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis. Biomaterials. 2015;61:162–177.
   PubMed Web of Science ®Google Scholar
• Meka RR, Venkatesha SH, Acharya B, et al. Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy. Nanomedicine. 2019;14(11):1455–1469.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao M, Yu C, et al. Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis. Int J Nanomedicine. 2017;12:6735.
   PubMed Web of Science ®Google Scholar
• Li P, Yang X, Yang Y, et al. Synergistic effect of all-trans-retinal and triptolide encapsulated in an inflammation-targeted nanoparticle on collagen-induced arthritis in mice. J Control Release. 2020;319:87–103.
   PubMed Web of Science ®Google Scholar
• Randolph GJ. Mechanisms that regulate macrophage burden in atherosclerosis. Circ Res. 2014;114(11):1757–1771.
   PubMed Web of Science ®Google Scholar
• Sanchez-Gaytan BL, Fay F, Lobatto ME, et al. HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages. Bioconjug Chem. 2015;26(3):443–451.
   PubMed Web of Science ®Google Scholar
• SHARMA G, SHE Z-G, VALENTA DT, et al. Targeting of macrophage foam cells in atherosclerotic plaque using oligonucleotide-functionalized nanoparticles. Nano Life. 2010;1(3–4):207.
   PubMedGoogle Scholar
• van der Valk FM, van Wijk DF, Lobatto ME, et al. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine. 2015;11(5):1039–1046.
   PubMed Web of Science ®Google Scholar
• Gao C, Huang Q, Liu C, et al. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat Commun. 2020;11(1):1–14.
   PubMed Web of Science ®Google Scholar
• Weiss G, Schaible UE. Macrophage defense mechanisms against intracellular bacteria. Immunol Rev. 2015;264(1):182–203.
   PubMed Web of Science ®Google Scholar
• Nairz M, Ferring-Appel D, Casarrubea D, et al. Iron regulatory proteins mediate host resistance to Salmonella infection. Cell Host Microbe. 2015;18(2):254–261.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Escobedo G, Gunn JS, McCormick BA. Gallbladder epithelium as a niche for chronic Salmonella carriage. Infect Immun. 2013;81(8):2920–2930.
   PubMed Web of Science ®Google Scholar
• Zaki NM, Hafez MM. Enhanced antibacterial effect of ceftriaxone sodium-loaded chitosan nanoparticles against intracellular Salmonella typhimurium. Aaps Pharmscitech. 2012;13(2):411–421.
   PubMed Web of Science ®Google Scholar
• Mudakavi RJ, Vanamali S, Chakravortty D, et al. Development of arginine based nanocarriers for targeting and treatment of intracellular Salmonella. RSC Adv. 2017;7(12):7022–7032.
   Web of Science ®Google Scholar
• Elbi S, Nimal TR, Rajan VK, et al. Fucoidan coated ciprofloxacin loaded chitosan nanoparticles for the treatment of intracellular and biofilm infections of Salmonella. Colloids Surf B Biointerfaces. 2017;160:40–47.
   PubMed Web of Science ®Google Scholar
• Tran T-H, Rastogi R, Shelke J, et al. Modulation of macrophage functional polarity towards anti-inflammatory phenotype with plasmid DNA delivery in CD44 targeting hyaluronic acid nanoparticles. Sci Rep. 2015;5(1):1–15.
   Google Scholar
• Parayath NN, Amiji MM Preparation of hyaluronic acid-based nanoparticles for macrophage-targeted MicroRNA delivery and transfection, In Nanoparticles in biology and medicine :Methods and Protocols, edited by Enrico Ferrari and Mikhail Soloviev, 99–110. Methods in Molecular Biology. New York, NY: Springer US. 2020. p. 99–110.
   Google Scholar
• Shahbazi M-A, Sedighi M, Bauleth-Ramos T, et al. Targeted reinforcement of macrophage reprogramming toward M2 polarization by IL-4-loaded hyaluronic acid particles. ACS Omega. 2018;3(12):18444–18455.
   PubMed Web of Science ®Google Scholar
• Badylak SF, Valentin JE, Ravindra AK, et al. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A. 2008;14(11):1835–1842.
   PubMed Web of Science ®Google Scholar
• Kim Y-H, Furuya H, Tabata Y. Enhancement of bone regeneration by dual release of a macrophage recruitment agent and platelet-rich plasma from gelatin hydrogels. Biomaterials. 2014;35(1):214–224.
   PubMed Web of Science ®Google Scholar
• Li T, Peng M, Yang Z, et al. 3D-printed IFN-γ-loading calcium silicate-β-tricalcium phosphate scaffold sequentially activates M1 and M2 polarization of macrophages to promote vascularization of tissue engineering bone. Acta Biomater. 2018;71:96–107.
   PubMed Web of Science ®Google Scholar
• Eren AD, Sinha R, Eren ED, et al. Decellularized porcine achilles tendon induces anti-inflammatory macrophage phenotype in vitro and tendon repair in vivo. J Immunol Regen Med. 2020;8:100027.
   Google Scholar
• Spiller KL, Freytes DO, Vunjak-Novakovic G. Macrophages modulate engineered human tissues for enhanced vascularization and healing. Ann Biomed Eng. 2015;43(3):616–627.
   PubMed Web of Science ®Google Scholar
• Hsu C-W, Poché RA, Saik JE, et al. Improved angiogenesis in response to localized delivery of macrophage-recruiting molecules. PloS One. 2015;10(7).
   Web of Science ®Google Scholar
• Harel-Adar T, Mordechai TB, Amsalem Y, et al. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc Nat Acad Sci. 2011;108(5):1827–1832.
   PubMed Web of Science ®Google Scholar
• Smits AIPM, Bouten CVC. Tissue engineering meets immunoengineering: prospective on personalized in situ tissue engineering strategies. Curr Opin Biomed Eng. 2018;6:17–26.
   Google Scholar
• Godwin JW, Debuque R, Salimova E, et al. Heart regeneration in the salamander relies on macrophage-mediated control of fibroblast activation and the extracellular landscape. NPJ Regen Med. 2017;2(1):1–11.
   PubMedGoogle Scholar
• *BARTHES JGD, Dollinger C, Muller CB, et al. Corrigendum: immune assisted tissue engineering via incorporation of macrophages in cell-laden hydrogels under cytokine stimulation. Front Bioeng Biotechnol. 2019;7:29.
   PubMed Web of Science ®Google Scholar
• Wu R-X, Ma C, Liang Y, et al. ECM-mimicking nanofibrous matrix coaxes macrophages toward an anti-inflammatory phenotype: cellular behaviors and transcriptome analysis. Appl Mater Today. 2020;18:100508.
   PubMed Web of Science ®Google Scholar
• Gou S, Huang Y, Wan Y, et al. Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis. Biomaterials. 2019;212:39–54.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhuang X, Deng Z-B, et al. Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol Ther. 2014;22(3):522–534.
   PubMed Web of Science ®Google Scholar
• Wei F, Lang Y, Shen Q, et al. Osteopontin-loaded PLGA nanoparticles enhance the intestinal mucosal barrier and alleviate inflammation via the NF-κB signaling pathway. Colloids Surf B Biointerfaces. 2020;190:110952.
   PubMed Web of Science ®Google Scholar
• Kunjachan S, Gupta S, Dwivedi AK, et al. Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis. J Microencapsul. 2011;28(4):301–310.
   PubMed Web of Science ®Google Scholar
• Monteiro LM, Löbenberg R, Ferreira EI, et al. Targeting Leishmania amazonensis amastigotes through macrophage internalisation of a hydroxymethylnitrofurazone nanostructured polymeric system. Int J Antimicrob Agents. 2017;50(1):88–92.
   PubMed Web of Science ®Google Scholar
• Esfandiari F, Motazedian MH, Asgari Q, et al. Paromomycin-loaded mannosylated chitosan nanoparticles: synthesis, characterization and targeted drug delivery against leishmaniasis. Acta Trop. 2019;197:105072.
   PubMed Web of Science ®Google Scholar
• Clemens DL, Lee B-Y, Xue M, et al. Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles. Antimicrob Agents Chemother. 2012;56(5):2535–2545.
   PubMed Web of Science ®Google Scholar
• Vieira AC, Magalhães J, Rocha S, et al. Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment. Nanomedicine. 2017;12(24):2721–2736.
   PubMed Web of Science ®Google Scholar
• Narayanasamy P, Switzer BL, Britigan BE. Prolonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages. Sci Rep. 2015;5(1):8824.
   PubMed Web of Science ®Google Scholar
• Shegokar R, Singh KK. Preparation, characterization and cell based delivery of stavudine surface modified lipid nanoparticles. Journal of Nanomedicine & Biotherapeutic Discovery. 2012;2(3):1–9.
   PubMedGoogle Scholar
• Gouveia VM, Lopes-de-Araújo J, Costa Lima SA, et al. Hyaluronic acid-conjugated pH-sensitive liposomes for targeted delivery of prednisolone on rheumatoid arthritis therapy. Nanomedicine. 2018;13(9):1037–1049.
   PubMed Web of Science ®Google Scholar
• Heo R, You DG, Um W, et al. Dextran sulfate nanoparticles as a theranostic nanomedicine for rheumatoid arthritis. Biomaterials. 2017;131:15–26.
   PubMed Web of Science ®Google Scholar
• Bilthariya U, Jain N, Rajoriya V, et al. Folate-conjugated albumin nanoparticles for rheumatoid arthritis-targeted delivery of etoricoxib. Drug Dev Ind Pharm. 2015;41(1):95–104.
   PubMed Web of Science ®Google Scholar
• Varasteh Z, Mohanta S, Li Y, et al. Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 68 Ga-NOTA-anti-MMR nanobody: non-invasive imaging of atherosclerotic plaques. EJNMMI Res. 2019;9(1):5.
   PubMedGoogle Scholar
• Tae H, Lee S, Ki CS. β-Glucan hybridized poly(ethylene glycol) microgels for macrophage-targeted protein delivery. J Ind Eng Chem. 2019;75:69–76.
   Web of Science ®Google Scholar
• Mudakavi RJ, Raichur AM, Chakravortty D. Lipid coated mesoporous silica nanoparticles as an oral delivery system for targeting and treatment of intravacuolar Salmonella infections. RSC Adv. 2014;4(105):61160–61166.
   Web of Science ®Google Scholar
• Sakhrani NM, Padh H. Organelle targeting: third level of drug targeting. Drug Des Devel Ther. 2013;7:585.
   PubMed Web of Science ®Google Scholar
• Kim J, Bae J-S. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016;2016:1–11.
   Web of Science ®Google Scholar
• Colvin EK. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol. 2014;4:137.
   PubMedGoogle Scholar
• Flecken T, Sarobe P. Tim-3 expression in tumour-associated macrophages: a new player in HCC progression. Gut. 2015;64(10):1502–1503.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Komohara Y, Ikeda T, et al. Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription‐3 and nuclear factor‐kappa B in tumor cells and tumor‐associated macrophages. Cancer Sci. 2011;102(1):206–211.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lin Y-X, Qiao S-L, et al. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials. 2017;112:153–163.
   PubMed Web of Science ®Google Scholar
• Su L, Zhang W, Wu X, et al. Glycocalyx‐mimicking nanoparticles for stimulation and polarization of macrophages via specific interactions. Small. 2015;11(33):4191–4200.
   PubMed Web of Science ®Google Scholar
• Niu M, Naguib YW, Aldayel AM, et al. Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin. Mol Pharm. 2014;11(12):4425–4436.
   PubMedGoogle Scholar
• Qian Y, Qiao S, Dai Y, et al. Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages. ACS Nano. 2017;11(9):9536–9549.
   PubMed Web of Science ®Google Scholar
• Locke LW, Mayo MW, Yoo AD, et al. PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes. Biomaterials. 2012;33(31):7785–7793.
   PubMed Web of Science ®Google Scholar
• Huang W-C, Chen S-H, Chiang W-H, et al. Tumor microenvironment-responsive nanoparticle delivery of chemotherapy for enhanced selective cellular uptake and transportation within tumor. Biomacromolecules. 2016;17(12):3883–3892.
   PubMed Web of Science ®Google Scholar
• Penn CA, Yang K, Zong H, et al. Therapeutic impact of nanoparticle therapy targeting tumor-associated macrophages. Mol Cancer Ther. 2018;17(1):96–106.
   PubMed Web of Science ®Google Scholar
• Zimel MN, Horowitz CB, Rajasekhar VK, et al. HPMA–copolymer nanocarrier targets tumor-associated macrophages in primary and metastatic breast cancer. Mol Cancer Ther. 2017;16(12):2701–2710.
   PubMed Web of Science ®Google Scholar
• Iwata H, Goettsch C, Sharma A, et al. PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation. Nat Commun. 2016;7(1):1–19.
   Google Scholar
• Gustafson HH, Holt-Casper D, Grainger DW, et al. Nanoparticle uptake: the phagocyte problem. Nano Today. 2015;10(4):487–510.
   PubMed Web of Science ®Google Scholar
• Mayor S, Parton RG, Donaldson JG. Clathrin-independent pathways of endocytosis. Cold Spring Harb Perspect Biol. 2014;6(6):a016758.
   PubMed Web of Science ®Google Scholar
• Kadiu I, Nowacek A, McMillan J, et al. Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine. 2011;6(6):975–994.
   PubMed Web of Science ®Google Scholar
• Moore TL, Hauser D, Gruber T, et al. Cellular shuttles: monocytes/macrophages exhibit transendothelial transport of nanoparticles under physiological flow. ACS Appl Mater Interfaces. 2017;9(22):18501–18511.
   PubMed Web of Science ®Google Scholar
• Low PS, Turk MJ. Treatment and diagnosis of macrophage mediated disease. Google Patents; 2008.
   Google Scholar
• Low PS, Turk MJ. Treatment of macrophage mediated disease. Google Patents; 2010.
   Google Scholar
• Kay H. Platinum complexes for targeted drug delivery. Google Patents; 2011.
   Google Scholar
• Gieseler RK, Marquitan G, Scolaro M, et al. Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells. Google Patents; 2016.
   Google Scholar
• Hulsmans M, Nahrendorf M, Weissleder R. Targeting macrophages to modulate electrical conduction in the heart. Google Patents; 2019.
   Google Scholar
• Tveita A. Fusion proteins targeting tumour associated macrophages for treating cancer. Google Patents; 2019.
   Google Scholar
• Vlahov IR, Leamon CP, Qi L, et al. Folate conjugate for use in targeting tumor associated macrophages. Google Patents; 2020.
   Google Scholar
• Paliwal R, Babu RJ, Palakurthi S. Nanomedicine scale-up technologies: feasibilities and challenges. Aaps Pharmscitech. 2014;15(6):1527–1534.
   PubMed Web of Science ®Google Scholar
• **Abid S, Marcos E, Parpaleix A, et al. CCR2/CCR5-mediated macrophage–smooth muscle cell crosstalk in pulmonary hypertension. Eur Respir J. 54(4):1802308. 2019.
   PubMed Web of Science ®Google Scholar